Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Urea

Classification: B

Drug products: Calmuril, Canoderm®, Caress®, Curemid, Fenuril®, Karbamid Evolan, Karbamid i Decubal® kräm APL, Karbamid i Essex B kräm APL, Karbamid i Essex kräm APL, Karbamid i Essex lotion APL, Karbamid i Locobase® kräm APL, Karbamid i Locobase® lotion APL, Karbamid NET, Karbasal, Karbiderm, Monilen

ATC code: D02AE01

Substances: urea, urea (C-13), urea (C-14)

Summary

Controlled studies on differences between men and women on efficacy, safety, and pharmacokinetics for carbamide are lacking.

Additional information

The main indication of carbamide preparations is moisturizing treatment of dry skin [2].

Pharmacokinetics and dosing

No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of carbamide have been found.

Effects

No studies with a clinically relevant sex analysis regarding the effect of carbamide have been found.

Adverse effects

No studies with a clinically relevant sex analysis regarding adverse effects of carbamide have been found.

Reproductive health issues

Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).

Other information

A retrospective analysis of patients with eczema or psoriasis on standard dermatological treatment (295 men, 291 women) found that significantly more men than women (79; 63%, 47; 37%) were administered whole-body UV treatment. Also, the results indicated that men had more treatments appointments per individual than women. Women were prescribed more emollients than men [1].

Updated: 2020-10-06

Date of litterature search: 2020-04-17

References

  1. Nyberg F, Osika I, Evengård B. "The Laundry Bag Project"--unequal distribution of dermatological healthcare resources for male and female psoriatic patients in Sweden. Int J Dermatol. 2008;47:144-9. PubMed
  2. Canoderm (carbamide). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2019-10-16, cited 2020-04-17]
  3. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.] länk

Authors: Linnéa Karlsson Lind

Reviewed by: Diana Rydberg, Carl-Olav Stiller

Approved by: Karin Schenck-Gustafsson